Vitrolife AB (publ) (VITR.ST)
SEK 154.7
(-1.84%)
SEK 154.7
(-1.84%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 5.56 Billion SEK | -12.23% |
| 2022 | 1.14 Billion SEK | 84.77% |
| 2021 | 619.67 Million SEK | 58.14% |
| 2020 | 391.86 Million SEK | -13.01% |
| 2019 | 450.46 Million SEK | 21.08% |
| 2018 | 372.05 Million SEK | 9.95% |
| 2017 | 338.37 Million SEK | 8.08% |
| 2016 | 313.08 Million SEK | 13.31% |
| 2015 | 276.29 Million SEK | 29.55% |
| 2014 | 213.27 Million SEK | -3.82% |
| 2013 | 221.73 Million SEK | 17.83% |
| 2012 | 188.18 Million SEK | -4.53% |
| 2011 | 197.1 Million SEK | 13.87% |
| 2010 | 173.09 Million SEK | 6.54% |
| 2009 | 162.47 Million SEK | 25.83% |
| 2008 | 129.12 Million SEK | 18.87% |
| 2007 | 108.63 Million SEK | 12.58% |
| 2006 | 96.49 Million SEK | 36.15% |
| 2005 | 70.87 Million SEK | 15.56% |
| 2004 | 61.33 Million SEK | 210.32% |
| 2003 | 19.76 Million SEK | 127.05% |
| 2002 | -73.05 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 261 Million SEK | 1.16% |
| 2024 Q1 | 258 Million SEK | 0.39% |
| 2024 Q3 | 335 Million SEK | 27.97% |
| 2023 FY | 1 Billion SEK | -12.23% |
| 2023 Q1 | 326 Million SEK | 3.82% |
| 2023 Q2 | 318 Million SEK | -2.45% |
| 2023 Q3 | 293 Million SEK | -7.86% |
| 2023 Q4 | 257 Million SEK | -12.29% |
| 2022 Q2 | 296 Million SEK | 3.86% |
| 2022 Q1 | 285 Million SEK | 6.02% |
| 2022 Q3 | 250 Million SEK | -15.54% |
| 2022 Q4 | 314 Million SEK | 25.6% |
| 2022 FY | 1.14 Billion SEK | 84.77% |
| 2021 Q1 | 104.48 Million SEK | 5.85% |
| 2021 Q2 | 125.99 Million SEK | 20.59% |
| 2021 Q4 | 268.82 Million SEK | 123.31% |
| 2021 FY | 619.67 Million SEK | 58.14% |
| 2021 Q3 | 120.38 Million SEK | -4.45% |
| 2020 Q4 | 98.7 Million SEK | 14.03% |
| 2020 FY | 391.86 Million SEK | -13.01% |
| 2020 Q2 | 94.78 Million SEK | -15.23% |
| 2020 Q3 | 86.55 Million SEK | -8.68% |
| 2020 Q1 | 111.81 Million SEK | -7.78% |
| 2019 Q3 | 112.87 Million SEK | -7.46% |
| 2019 Q4 | 121.24 Million SEK | 7.42% |
| 2019 Q2 | 121.97 Million SEK | 29.24% |
| 2019 FY | 450.46 Million SEK | 21.08% |
| 2019 Q1 | 94.37 Million SEK | -19.7% |
| 2018 Q4 | 117.53 Million SEK | 40.22% |
| 2018 Q2 | 88.85 Million SEK | 8.57% |
| 2018 Q3 | 83.81 Million SEK | -5.67% |
| 2018 Q1 | 81.84 Million SEK | -3.31% |
| 2018 FY | 372.05 Million SEK | 9.95% |
| 2017 Q4 | 84.64 Million SEK | 2.94% |
| 2017 FY | 338.37 Million SEK | 8.08% |
| 2017 Q2 | 92 Million SEK | 15.75% |
| 2017 Q1 | 79.48 Million SEK | -12.42% |
| 2017 Q3 | 82.23 Million SEK | -10.62% |
| 2016 Q3 | 74.22 Million SEK | -0.96% |
| 2016 FY | 313.08 Million SEK | 13.31% |
| 2016 Q1 | 73.15 Million SEK | -13.46% |
| 2016 Q2 | 74.94 Million SEK | 2.44% |
| 2016 Q4 | 90.76 Million SEK | 22.28% |
| 2015 FY | 276.29 Million SEK | 29.55% |
| 2015 Q4 | 84.54 Million SEK | 58.18% |
| 2015 Q1 | 66.98 Million SEK | 8.62% |
| 2015 Q2 | 71.33 Million SEK | 6.49% |
| 2015 Q3 | 53.44 Million SEK | -25.08% |
| 2014 Q2 | 55.44 Million SEK | 8.71% |
| 2014 Q1 | 51 Million SEK | -19.32% |
| 2014 FY | 213.27 Million SEK | -3.82% |
| 2014 Q4 | 61.66 Million SEK | 36.55% |
| 2014 Q3 | 45.16 Million SEK | -18.55% |
| 2013 FY | 221.73 Million SEK | 17.83% |
| 2013 Q2 | 57.5 Million SEK | 11.31% |
| 2013 Q1 | 51.66 Million SEK | 1.43% |
| 2013 Q3 | 49.36 Million SEK | -14.16% |
| 2013 Q4 | 63.21 Million SEK | 28.07% |
| 2012 FY | 188.18 Million SEK | -4.53% |
| 2012 Q3 | 40.29 Million SEK | -19.2% |
| 2012 Q4 | 50.93 Million SEK | 26.39% |
| 2012 Q1 | 52.78 Million SEK | -12.4% |
| 2012 Q2 | 49.87 Million SEK | -5.52% |
| 2011 Q1 | 48.66 Million SEK | 5.31% |
| 2011 FY | 197.1 Million SEK | 13.87% |
| 2011 Q4 | 60.26 Million SEK | 39.02% |
| 2011 Q3 | 43.34 Million SEK | -3.33% |
| 2011 Q2 | 44.83 Million SEK | -7.87% |
| 2010 Q1 | 41.79 Million SEK | 3.13% |
| 2010 Q2 | 43.3 Million SEK | 3.6% |
| 2010 Q3 | 41.78 Million SEK | -3.5% |
| 2010 Q4 | 46.21 Million SEK | 10.6% |
| 2010 FY | 173.09 Million SEK | 6.54% |
| 2009 FY | 162.47 Million SEK | 25.83% |
| 2009 Q2 | 42.24 Million SEK | 0.0% |
| 2009 Q4 | 40.52 Million SEK | 3.12% |
| 2009 Q3 | 39.3 Million SEK | -6.96% |
| 2008 FY | 129.12 Million SEK | 18.87% |
| 2007 FY | 108.63 Million SEK | 12.58% |
| 2006 FY | 96.49 Million SEK | 36.15% |
| 2005 FY | 70.87 Million SEK | 15.56% |
| 2004 FY | 61.33 Million SEK | 210.32% |
| 2003 FY | 19.76 Million SEK | 127.05% |
| 2002 FY | -73.05 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Acarix AB (publ) | 82.85 Million SEK | -6619.372% |
| ADDvise Group AB (publ) | 611.8 Million SEK | -809.938% |
| ADDvise Group AB (publ) | 611.8 Million SEK | -809.938% |
| Arcoma AB | 53.25 Million SEK | -10354.067% |
| Bactiguard Holding AB (publ) | 4.96 Million SEK | -111934.615% |
| BICO Group AB (publ) | 2.84 Billion SEK | -95.443% |
| Boule Diagnostics AB (publ) | 210.44 Million SEK | -2545.359% |
| CellaVision AB (publ) | 295.99 Million SEK | -1780.807% |
| Clinical Laserthermia Systems AB (publ) | 68.93 Million SEK | -7976.309% |
| Chordate Medical Holding AB (publ) | 1.3 Million SEK | -425127.031% |
| C-Rad AB (publ) | 3.8 Million SEK | -146400.0% |
| Duearity AB (publ) | 21.58 Million SEK | -25691.059% |
| Dignitana AB (publ) | 74.73 Million SEK | -7348.887% |
| Episurf Medical AB (publ) | 2.7 Million SEK | -206085.185% |
| Getinge AB (publ) | 10.75 Billion SEK | 48.257% |
| Scandinavian Real Heart AB (Publ) | 18.22 Million SEK | -30439.988% |
| Iconovo AB (publ) | 63.35 Million SEK | -8687.075% |
| Integrum AB (publ) | 90.57 Million SEK | -6046.524% |
| Luxbright AB (publ) | 23.09 Million SEK | -24009.463% |
| Mentice AB (publ) | 237.06 Million SEK | -2248.351% |
| OssDsign AB (publ) | 175.6 Million SEK | -3070.255% |
| Paxman AB (publ) | 133.8 Million SEK | -4060.688% |
| Promimic AB (publ) | 48.55 Million SEK | -11366.057% |
| Qlife Holding AB (publ) | 162.38 Million SEK | -3328.272% |
| SciBase Holding AB (publ) | 69.97 Million SEK | -7855.585% |
| ScandiDos AB (publ) | 61.03 Million SEK | -9020.548% |
| Sectra AB (publ) | 39.06 Million SEK | -14151.338% |
| Sedana Medical AB (publ) | 174.52 Million SEK | -3089.746% |
| Senzime AB (publ) | 141.51 Million SEK | -3833.803% |
| SpectraCure AB (publ) | 12.12 Million SEK | -45802.045% |
| Stille AB | 87.21 Million SEK | -6282.784% |
| Xvivo Perfusion AB (publ) | 440.92 Million SEK | -1162.576% |